FindTrial
Sign In

Gemcitabine,cisplatin

DRUG4 trials

Sponsors

Fudan University, Wei Jiang

Conditions

Breast CancerNasopharyngeal Carcinoma

Phase 2

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)
NCT02341911
Fudan UniversityBreast Cancer
Start: 2015-01-31End: 2022-12-31Target: 150Updated: 2022-04-20
Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)
NCT04517292
Fudan UniversityBreast Cancer
Start: 2020-10-08End: 2022-10-31Target: 160Updated: 2020-08-18

Phase 3

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)
CompletedNCT01287624
Fudan UniversityBreast Cancer
Start: 2011-01-31End: 2014-03-31Updated: 2015-03-23
Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
RecruitingNCT05527470
Wei JiangNasopharyngeal Carcinoma
Start: 2022-11-11End: 2027-11-11Target: 440Updated: 2023-05-03

Related Papers

Abstract PO2-06-11: A phase II randomized trial of gemcitabine plus cisplatin(GP) vs gemcitabine plus carboplatin (GC) as the first-line treatment for patients with metastatic triple-negative breast cancer
Cancer Research2024-05-021 citations
A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer.
2022-07-1252 citations
Abstract PS12-11: Phase 1b clinical trial of HX008, a novel anti-PD-1 monoclonal antibody, Combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer
Cancer Research2021-02-151 citations
<p>Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a “PET biopsy” method</p>
Cancer Management and Research2019-07-015 citations
Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer.
2019-03-054 citations
Pretreatment 18F-FDG Uptake Heterogeneity Predicts Treatment Outcome of First-Line Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer
The Oncologist2018-08-0627 citations
Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
2018-08-0155 citations
Updated survival data and biomarker assessment of the CBCSG006 trial: A randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
Journal of Clinical Oncology2018-05-20
Abstract OT2-05-01: A phase II randomized trial of gemcitabine plus cisplatin(GP) vs. gemcitabine plus carboplatin (GC) as the first-line treatment for patients with metastatic triple negative breast cancer
Cancer Research2018-02-15
Abstract P3-10-02: Gemcitabine with cisplatin or paclitaxel in metastatic triple-negative breast cancer
Cancer Research2015-05-01
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
2015-03-18206 citations